JP7539485B2 - ピラゾール誘導体の肺線維症治療剤 - Google Patents

ピラゾール誘導体の肺線維症治療剤 Download PDF

Info

Publication number
JP7539485B2
JP7539485B2 JP2022562440A JP2022562440A JP7539485B2 JP 7539485 B2 JP7539485 B2 JP 7539485B2 JP 2022562440 A JP2022562440 A JP 2022562440A JP 2022562440 A JP2022562440 A JP 2022562440A JP 7539485 B2 JP7539485 B2 JP 7539485B2
Authority
JP
Japan
Prior art keywords
pulmonary fibrosis
compound
virus
pyrazol
pyridin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2022562440A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023522628A (ja
JP2023522628A5 (enExample
Inventor
スン・ファン・ムン
ス・ジン・イ
ヒュンキュン・ユ
ユ－キュン・ゴ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
APTABIO THERAPEUTICS Inc
Original Assignee
APTABIO THERAPEUTICS Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from KR1020210036863A external-priority patent/KR102386097B1/ko
Application filed by APTABIO THERAPEUTICS Inc filed Critical APTABIO THERAPEUTICS Inc
Publication of JP2023522628A publication Critical patent/JP2023522628A/ja
Publication of JP2023522628A5 publication Critical patent/JP2023522628A5/ja
Application granted granted Critical
Publication of JP7539485B2 publication Critical patent/JP7539485B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2022562440A 2020-04-13 2021-03-23 ピラゾール誘導体の肺線維症治療剤 Active JP7539485B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
KR10-2020-0044598 2020-04-13
KR20200044598 2020-04-13
KR10-2021-0036863 2021-03-22
KR1020210036863A KR102386097B1 (ko) 2020-04-13 2021-03-22 피라졸 유도체의 폐섬유증 치료제
PCT/KR2021/003537 WO2021210799A1 (ko) 2020-04-13 2021-03-23 피라졸 유도체의 폐섬유증 치료제

Publications (3)

Publication Number Publication Date
JP2023522628A JP2023522628A (ja) 2023-05-31
JP2023522628A5 JP2023522628A5 (enExample) 2024-01-05
JP7539485B2 true JP7539485B2 (ja) 2024-08-23

Family

ID=78083982

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022562440A Active JP7539485B2 (ja) 2020-04-13 2021-03-23 ピラゾール誘導体の肺線維症治療剤

Country Status (12)

Country Link
US (1) US12616684B2 (enExample)
EP (1) EP4137134A4 (enExample)
JP (1) JP7539485B2 (enExample)
KR (2) KR102567012B1 (enExample)
CN (1) CN115427039B (enExample)
AU (1) AU2021255160B2 (enExample)
BR (1) BR112022020649A2 (enExample)
CA (1) CA3172596A1 (enExample)
CL (1) CL2022002642A1 (enExample)
CO (1) CO2022014273A2 (enExample)
MX (1) MX2022012726A (enExample)
WO (1) WO2021210799A1 (enExample)

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20040094464A (ko) * 2003-05-02 2004-11-10 학교법인 이화학당 피리디닐 피라졸 유도체
KR20120054077A (ko) 2009-08-21 2012-05-29 길리아드 바이오로직스, 인크. 폐 섬유증 장애의 치료를 위한 방법 및 조성물
WO2011028043A2 (ko) 2009-09-02 2011-03-10 이화여자대학교 산학협력단 피라졸 유도체, 이의 제조방법 및 이를 포함하는 골다공증 예방 및 치료용 조성물
KR101302315B1 (ko) * 2011-07-19 2013-08-30 이화여자대학교 산학협력단 피라졸 유도체를 포함하는 호흡기 질환 예방 및 치료용 조성물
KR101633957B1 (ko) 2012-08-27 2016-06-27 이화여자대학교 산학협력단 피라졸 유도체를 포함하는 신장질환 예방 또는 치료용 조성물
US10548911B2 (en) * 2014-06-16 2020-02-04 University Of Rochester Small molecule anti-scarring agents
US11096952B2 (en) * 2016-02-02 2021-08-24 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Chemicals and methods to prevent and treat TGF-beta mediated activation of fibroblasts to reduce and treat cancer and fibrosis
WO2017192304A1 (en) 2016-05-02 2017-11-09 Inception 1, Inc. Arylcarboxamides and uses thereof
CA3046158A1 (en) 2017-01-27 2018-08-02 Genfit Pharmaceutical compositions for combination therapy
KR101821593B1 (ko) 2017-02-23 2018-01-25 압타바이오 주식회사 안질환 치료제
IL268751B (en) 2017-03-13 2022-08-01 Genfit Pharmaceutical preparations for combined treatment
CN110536683A (zh) 2017-04-18 2019-12-03 基恩菲特公司 包含PPAR激动剂如伊拉非诺和乙酰CoA羧化酶ACC抑制剂的组合
KR101856444B1 (ko) 2017-04-20 2018-05-10 압타바이오 주식회사 3-페닐-4-프로필-1-(피리딘-2-일)-1ｈ-피라졸-5-올 염산염의 신규 결정형 고체 화합물
KR101840702B1 (ko) * 2017-11-01 2018-03-22 압타바이오 주식회사 간질환 치료제
TWI815938B (zh) 2018-08-01 2023-09-21 日商日本化藥股份有限公司 具有n-烷基的芳香族胺樹脂、硬化性樹脂組成物及其硬化物
EP3628669A1 (en) 2018-09-28 2020-04-01 GenKyoTex Suisse SA Novel compounds as nadph oxidase inhibitors
KR102207340B1 (ko) 2018-10-19 2021-01-22 한남대학교 산학협력단 표면 개질된 다공성 탄소복합소재 및 그 제조방법
CN109912600B (zh) * 2019-02-22 2021-08-03 四川大学华西医院 一种防治肺纤维化的咪唑并嘧啶类衍生物及其应用
MX2022012472A (es) 2020-04-08 2022-12-15 Aptabio Therapeutics Inc Agente para el tratamiento de lesion renal aguda inducida por medio de contraste.
WO2021263281A2 (en) * 2020-06-26 2021-12-30 Ann And Robert H. Lurie Children's Hospital Of Chicago Methods and compositions for the treatment of covid-19 and associated respiratory distress and multi-organ failure, sepsis, acute respiratory distress syndrome, and cordiovascular diseases
UY39671A (es) 2021-03-15 2022-10-31 Novartis Ag Derivados de pirazolopiridina y sus usos.

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Oxidative Medicine and Cellular Longevity，Volume 2015，2015年，p.1-10
Pharmacology，102 (3-4)，2018年，p.180-189

Also Published As

Publication number Publication date
WO2021210799A1 (ko) 2021-10-21
KR20210146871A (ko) 2021-12-06
EP4137134A1 (en) 2023-02-22
US20230148365A1 (en) 2023-05-11
MX2022012726A (es) 2022-11-07
KR20220039687A (ko) 2022-03-29
CN115427039B (zh) 2025-04-04
BR112022020649A2 (pt) 2022-11-29
AU2021255160B2 (en) 2024-02-01
CA3172596A1 (en) 2021-10-21
JP2023522628A (ja) 2023-05-31
CL2022002642A1 (es) 2023-06-16
EP4137134A4 (en) 2024-08-07
KR102567012B1 (ko) 2023-08-14
CO2022014273A2 (es) 2022-10-21
AU2021255160A1 (en) 2022-10-06
US12616684B2 (en) 2026-05-05
CN115427039A (zh) 2022-12-02

Similar Documents

Publication Publication Date Title
JP7492002B2 (ja) Ｌｓｄ１阻害剤によりｌｓｄ１関連疾患及び障害を治療する方法
KR102347721B1 (ko) 섬유성 질환의 치료에 사용하기 위한 ppar 화합물
JP2019513762A (ja) 胆汁うっ滞及び線維症の処置方法
JP2024531188A5 (enExample)
JP5457196B2 (ja) Ｃｎｄａｃ（２’−シアノ−２’−デオキシ−ｎ４−パルミトイル−１−ベータ−ｄ−アラビノフラノシル−シトシン）及び細胞毒性薬を含む組合せ
US20110166149A1 (en) Pteridine derivatives for treating respiratory disease
JP2026069500A (ja) 線維症を治療するためのシクロスポリン類似体の使用
KR102784577B1 (ko) 인간 및 동물에서 알레르기 질환 및 다른 질환의 치료를 위한 말론산의 비스아미드 유도체의 용도
KR102567012B1 (ko) 피라졸 유도체의 폐섬유증 치료제
JP7749661B2 (ja) 心不全の処置のためのクロマノール化合物
RU2817989C1 (ru) Средство для лечения фиброза легких, содержащее производное пиразола
KR102386097B1 (ko) 피라졸 유도체의 폐섬유증 치료제
CN106999468B (zh) 熊脱氧胆酸和水飞蓟素改进cpt-11疗效和毒性的制药用途
WO2021202947A1 (en) Method for treating lung disease with cell-free amniotic fluid
US20110054179A1 (en) Mmp-2 and/or mmp-9 inhibitor
WO2021260560A1 (ko) 폐섬유화증 치료용 조성물
EP1908473B1 (en) Clarithromycin or salt thereof for use in the treatment pulmonary emphysema
US10364230B2 (en) Chromene-2 derivatives and use thereof in the treatment of fibrosis
CN114569615B (zh) 甲氨蝶呤类似物用于治疗炎症性皮肤疾病的用途
KR102595271B1 (ko) 니클로스아마이드 및 수니티닙을 포함하는 신장암 예방 또는 치료용 약학적 조성물
WO2026098636A1 (zh) Pde4抑制剂用于治疗和/或预防肺部疾病的用途
KR20260060207A (ko) 펜타데카노산 또는 이의 약학적으로 허용 가능한 염을 유효성분으로 포함하는 특발성 폐섬유증 예방 또는 치료용 약학적 조성물
HK40119287A (zh) 三并环类化合物的药物组合物
CN117562915A (zh) 一种腺苷衍生物在制备预防、缓解或治疗纤维化疾病的药物中的应用
CN116270663A (zh) 胆汁酸及其衍生物在治疗呼吸道炎症性疾病中的应用

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20221012

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230904

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20231204

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20231222

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20240318

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240718

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20240726

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20240805

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20240813

R150 Certificate of patent or registration of utility model

Ref document number: 7539485

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150